NEW APPROACHES TO BRAIN TUMOR THERAPY CNS CONSORTIUM

脑肿瘤治疗新方法 CNS 联盟

• 批准号: 7602575
• 负责人: HENRY BREM
• 金额: $ 3.45万
• 依托单位: HUGO W. MOSER RES INST KENNEDY KRIEGER
• 依托单位国家: 美国
• 财政年份: 2007
• 资助国家: 美国
• 起止时间: 2007-09-01 至 2008-08-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/7602575
• 关键词: Adult; Alabama; Biological Response Modifier Therapy; Biology; Biometry; Brain; Brain Neoplasms; Cancer Center; Caring; Clinical; Clinical Trials; Clinical Trials Design; Computer Retrieval of Information on Scientific Projects Database; Controlled Study; Data; Detection; Development; Diagnosis; Diagnostic Specificity; Employee Strikes; Evaluation; Funding; General Hospitals; Grant; Health Sciences; Human; Imaging Techniques; Institution; Laboratories; Lesion; Magnetic Resonance Imaging; Malignant Neoplasms; Methodology; Modality; Monitor; Multi-Institutional Clinical Trial; National Cancer Institute; Necrosis; Neuraxis; New Agents; Numbers; Outcome; Patient Care Team; Patients; Peer Review; Pennsylvania; Pharmacology; Phase; Physiological; Quality Control; Quality of life; Radiation; Radiosurgery; Research; Research Personnel; Research Project Grants; Resources; Route; Source; Specimen; Texas; Therapeutic; United States National Institutes of Health; Universities; Ursidae Family; Washington; base; chemotherapy; clinically relevant; data management; design; driving force; drug development; experience; forest; improved; multidisciplinary; neuroimaging; neuropathology; neurosurgery; novel strategies; oncology; organizational structure; protocol development; research clinical testing; size; treatment effect; tumor

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. The CNS consortium titled New Approaches To Brain Tumor Therapy (NABTT) is specifically designed to combine and focus the experience, resources and capabilities of thirteen outstanding institutions (Brown University, Columbia University, Emory University, Henry Ford Health Science Center, Johns Hopkins, Mass General Hospital, Lee Moffitt Cancer Center, Northwestern University, University of Alabama, University of Pennsylvania, University of Texas-San Antonio, Wake Forest University, and Washington University) to bear on primary brain tumors. The size of the consortium has grown from seven to thirteen institutions. This expands the consortiums ability to carry out clinical trials, broadens the laboratory research resources from which to develop new clinical trials, expands the cooperative, interactive theme which is the driving force behind this NCI sponsored RFA. The primary objective of the NABTT CNS Consortium is to improve the therapeutic outcome for adults with primary brain tumors. This consortium is one of two nationwide that is funded by the National Cancer Institute to conduct Phase I and II clinical evaluations of promising new treatment strategies (surgery, radiation, chemotherapy, and biologic therapies), routes of admistration, and clinical trial design in the treatment of primary malignancies of the central nervous system. The participating institutions have (1) a large number of adult patients with primary brain tumors, (2) expert multidisciplinary clinical teams caring for these patients, (3) extensive clinical and laboratory resources, (4) a striking number of ongoing high quality, clinically relevant, peer-reviewed and NIH funded clinical and laboratory brain tumor research projects, (5) nationally recognized expertise in oncology, pharmacology, new drug development, Phase I and II clinical trials, neurosurgery, and neuropathology, (6) extensive expertise in biostatistics, data management, and the coordination of multi-institutional studies, and (7) exceptional reputations for excellence in clinical care and research. The consortium adds to these strengths with a well-defined and smoothly functioning organizational structure, and emphasis on clinical trial design, protocol development, quality control, study monitoring, and data management and analysis. The secondary objective of the NABTT CNS Consortium is to share human brain tumor specimens and clinical and laboratory data to conduct additional research pertaining to (1) the basic biology of primary brain tumors, (2) the neuro-pharmacology of new therapies for primary brain tumors, and (3) improving the care and quality of life of adults with primary brain tumors. Our hypothesis is that therapeutic progress for brain tumor patients will arise from treatments rationally developed based on laboratory hypothesis driven research. Furthermore, that effective new treatments will be developed most efficiently through well controlled multi-institutional clinical trials. The primary long-term objective of this proposal is thus to improve the therapeutic outcome for adults with primary brain tumors. This will be accomplished by participating in Phase I and II clinical evaluations of promising new agents, biologic approaches, and routes of administration in the treatment of primary malignancies of the central nervous system (CNS) through the CNS. The proper diagnosis of tumor status upon initial presentation and the evaluation of the effect of treatment using multi-modality neuroimaging approaches are integral and essential parts of this aim. Conventional MRI is extremely sensitive for the detection of brain lesions; however, its diagnostic specificity, such as its ability to distinguish tumor type, grade, or separate tumor regrowth from radiation necrosis, is limited. As such, we have benefited greatly from the developments in the Research Resource over the past 4 years allowing to acquire more modalities (particularly physiological imaging techniques) more rapidly at 3T, and we will collaborate actively in evaluating the promising new methodologies that are being designed in TRDs 1-3.

这个子项目是许多研究子项目中的一个 由NIH/NCRR资助的中心赠款提供的资源。子项目和 研究者（PI）可能从另一个NIH来源获得了主要资金， 因此可以在其他CRISP条目中表示。所列机构为 研究中心，而研究中心不一定是研究者所在的机构。 CNS联盟， 脑肿瘤治疗新方法（NABTT） 专门设计用于联合收割机 并集中13所优秀院校的经验、资源和能力（布朗大学， 哥伦比亚大学，埃默里大学，亨利福特健康科学中心，约翰霍普金斯，麻省总医院， 李莫菲特癌症中心，西北大学，亚拉巴马大学，宾夕法尼亚大学， （德克萨斯-圣安东尼奥、维克森林大学和华盛顿大学）对原发性脑肿瘤的作用。的 该联盟的规模已从7个机构扩大到13个机构。这扩大了财团携带能力 临床试验，扩大了实验室研究资源，从开发新的临床试验，扩大了 合作，互动的主题，这是NCI赞助RFA背后的驱动力。 NABTT CNS联盟的主要目标是改善成人原发性高血压的治疗结果。 脑瘤 该联盟是由国家癌症研究所资助的两个全国性联盟之一， I期和II期临床评价有前途的新治疗策略（手术，放疗，化疗， 生物疗法）、给药途径和治疗原发性恶性肿瘤的临床试验设计。 中枢神经系统参与机构有（1）大量的成年原发性脑 肿瘤，（2）专家多学科临床团队照顾这些患者，（3）广泛的临床和实验室 资源，（4）大量正在进行的高质量，临床相关，同行评审和NIH资助的临床研究 和实验室脑肿瘤研究项目，（5）国家认可的肿瘤学，药理学，新的 药物开发，I期和II期临床试验，神经外科和神经病理学，（6）在以下方面的广泛专业知识 生物统计学、数据管理和多机构研究的协调，以及（7）卓越的声誉 在临床护理和研究方面的卓越表现。 该联盟通过一个明确的、 顺利运作的组织结构，并强调临床试验设计，方案制定，质量 控制、研究监查以及数据管理和分析。 NABTT CNS联盟的次要目标是分享人类脑肿瘤标本和临床研究， 实验室数据进行额外的研究有关（1）原发性脑肿瘤的基础生物学，（2） 原发性脑肿瘤新疗法的神经药理学，以及（3）改善患者的护理和生活质量。 患有原发性脑肿瘤的成年人。 我们的假设是，脑肿瘤患者的治疗进展将来自合理开发的治疗方法 基于实验室假设驱动的研究。此外，将开发有效的新治疗方法 最有效的方法是通过良好控制的多机构临床试验。这一长期目标的主要目的是 因此，本发明的建议是改善患有原发性脑肿瘤的成人的治疗结果。这将是 通过参与有前途的新药物，生物方法， 治疗中枢神经系统（CNS）原发性恶性肿瘤的方法和给药途径 通过CNS。在初次就诊时正确诊断肿瘤状态并评估 使用多模态神经成像方法的治疗是该目标的不可或缺的重要部分。常规 MRI对于脑病变的检测是非常敏感的;然而，其诊断特异性，例如其检测脑损伤的能力， 区分肿瘤类型、分级或将肿瘤再生与放射性坏死分开是有限的。因此，我们 在过去的4年里，我从研究资源的发展中受益匪浅， 我们将在以下方面积极合作： 评估TRD 1-3中正在设计的有前途的新方法。